Login to Your Account



Capstone Crushed on Phase IIa Data; Firm Optimistic

By Jennifer Boggs


Wednesday, December 15, 2010
Shares of Capstone Therapeutics were walloped after data from Phase IIa pilot trials testing antifibrotic peptide AZX100 in keloid scarring fell short of showing statistical significance, but company executives maintained that the drug warrants further development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription